Developing mouthswab patient friendly testing combined with determining African/Asian incidence of a biomarker to reduce risks of adverse birth outcomes using a novel pharmacogenomic test

点击翻译按钮获取中文摘要

COVID19 has required face to face contact with patients to be as limited as possible thus making obtaining clinical trial samples very difficult.The project comprises using mouthswabs to gain access to patients DNA to genotype for the incidence of a biomarker associated with adverse birth outcomes and include the results in a large clinical study. These patients account for a high proportion of deliveries in large city hospitals and have a higher risk of adverse birth outcomes for reasons as yet unknown. Mouthswabs will allow patients to be tested without need of visiting clinics to provide a blood sample.